VCYT : Summary for Veracyte, Inc. - Yahoo Finance

U.S. Markets open in 6 hrs 19 mins

Veracyte, Inc. (VCYT)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.69-0.02 (-0.26%)
At close: 4:00PM EST
People also watch
NSTGOXFDFMIVSTMCDNA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close7.71
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range7.56 - 7.80
52 Week Range4.21 - 8.45
Volume46,125
Avg. Volume144,685
Market Cap252.73M
Beta1.99
PE Ratio (TTM)-6.12
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube28 days ago

    ETFs with exposure to Veracyte, Inc. : December 22, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Veracyte, Inc. Here are 5 ETFs with the largest exposure to VCYT-US. Comparing the performance and risk of Veracyte, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 4 Growth Stocks to Buy Amid Obamacare Repeal Talks
    Zackslast month

    4 Growth Stocks to Buy Amid Obamacare Repeal Talks

    Affordable Care Act (ACA) has been one of the most discussed topics during the 2016 U.S. presidential election. Even after a month, it has been contributing to the discord in the healthcare investment market.

  • PR Newswirelast month

    Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 13, 2016 /PRNewswire/ -- Veracyte, Inc. (VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that Kevin K. Gordon, former chief operating officer of Quintiles Transnational Holdings Inc., has been appointed to the company's board of directors. Veracyte also announced that Brian Atwood, who has served as director and chairman since the company's founding, has elected to step down from the board. Concurrently, Bonnie Anderson, Veracyte's president and chief executive officer, has assumed the additional role of chairman of the board and John L. Bishop will become the lead independent director.